Alopecia Areata

Below is a list of our alopecia areata studies that are currently enrolling.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata BRAVE-AA1

  • Population: Black or African American Patients at least 18 years and ≤60 years for males (≤70 years of age for females)
  • Study Condition: Severe Alopecia Areata
  • Study Design: Participation in this research study will take approximately 61 weeks with 12 visits in that time. This research study includes three phases; a screening phase, treatment phase, and a follow-up phase. The length of the screening period varies from 5 to 35 days, depending on therapies that must be washed out or discontinued before initiation of treatment. Patients who meet all eligibility criteria will proceed to initiation of therapy and begin the 52 weeks open-label treatment. All subjects will take baricitinib 4mg once a day during the treatment period. The post-treatment follow-up visit will occur approximately 28 days after the last study drug dose.
  • Compensation will be provided

 

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to Less than 18 Years of Age with Alopecia Areata

  • Population: Patients aged 6 years to less than 18 years
  • Study Condition: Severe Alopecia Areata
  • Study Design: This is a Phase 3, placebo-controlled, randomized, double-blind research study evaluating the efficacy, safety, and PK of baricitinib in children from 6 years to less than 18 years of age with severe alopecia areata. The study is divided into 4 periods: a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week posttreatment follow-up period. If the subject meets all eligibility criteria they will be randomized to receive either baricitinib high dose, baricitinib low dose, or placebo for 36 weeks. Participants will then be transitioned into the long-term extension treatment period. Subjects will attend 18 clinic visits for up to 145 weeks.
  • Compensation may be provided

 

Please contact Dr. Veronica Emmerich for more information regarding ongoing alopecia areata studies.

Email: emmerich@musc.edu

Phone: 843-876-0110